Current status and prospects of neoadjuvant therapy for resectable pancreatic cancer / 中华外科杂志
Chinese Journal of Surgery
;
(12): 546-549, 2023.
Article
Dans Chinois
| WPRIM
| ID: wpr-985806
ABSTRACT
Pancreatic cancer is a highly malignant tumor. About 75% of patients with pancreatic cancer who underwent radical surgical resection will still experience postoperative recurrence. Neoadjuvant therapy could improve outcomes in patients with borderline resectable pancreatic cancer,has become a consensus;however it is still controversial in resectable pancreatic cancer. Limited high-quality randomized controlled trial studies support the routine initiation of neoadjuvant therapy in resectable pancreatic cancer. With the development of new technologies, such as next-generation sequencing, liquid biopsy, imaging omics, and organoids, patients are expected to benefit from the precision screening of potential candidates for neoadjuvant therapy and individualized treatment strategy.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Tumeurs du pancréas
/
Traitement néoadjuvant
Limites du sujet:
Humains
langue:
Chinois
Texte intégral:
Chinese Journal of Surgery
Année:
2023
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS